Riskpilot← Back to searchSign inGet full accessSanopharma AB
ABActiveOrg 5569204067Västra Särövägen 81Retail sale of pharmaceutical products · NACE 4773Est. 20130 employees
Revenue 2025
SEK 1,1M
-1% vs 2024
EBITDA margin
26.2%
-7% vs 2024
Equity ratio
49.9%
Financial strength
Net profit 2025
SEK 219K
+16% vs 2024
| Revenue | SEK 1,1M | -1% |
| EBITDA | SEK 280K | -7% |
| Net profit | SEK 219K | +16% |
| Total assets | SEK 1,2M | +41% |
| Equity | SEK 602K | +57% |
| Employees | 0 | — |
Legal name
Sanopharma AB
Org number
5569204067
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
25 januari 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolagets verksamhet är handel med, distribution och försäljning av hälso-, sjuk- och friskvård, såsom handel med läkemedel, medicinteknik och andra läkemedelsnära produkter. Företaget skall även bedriva handel och förvaltning av värdepapper och fastigheter och därmed förenlig verksamhet. Därutöver skall företaget erbjuda konsulttjänster inom market intelligence för mat, dryck, skönhet och personlig vård.
Address
Västra Särövägen 81
Email
gustav@sanopharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 052 | 793 | 652 | 1 085 | 1 069 |
| Staff expenses | — | — | — | — | −4 |
| EBITDA | 62 | 235 | 12 | 300 | 280 |
| Depreciation & amort. | −50 | −33 | — | — | — |
| EBIT | 12 | 202 | 12 | 300 | 280 |
| Net financials | — | — | −2 | −5 | −4 |
| Profit before tax | 12 | 202 | 10 | 230 | 277 |
| Tax | −0 | −0 | — | −42 | −58 |
| Net profit | 12 | 202 | 10 | 188 | 219 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 802 | 726 | 424 | 857 | 1 206 |
| Equity | 62 | 265 | 195 | 383 | 602 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 740 | 461 | 229 | 409 | 539 |
| Total debt | 740 | 461 | 229 | 409 | 539 |
EBITDA margin
26.2%
This company
15.8%
Market median
+66% vs market
20212025
Equity ratio
49.9%
This company
38.2%
Market median
+31% vs market
20212025
Return on equity
36.4%
This company
18.4%
Market median
+98% vs market
20212025
Net profit margin
20.5%
This company
8.1%
Market median
+153% vs market
20212025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20212025
Debt / equity
1.01×
This company
0.62×
Market median
-63% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CG Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Former (1) | ||
| Board of Directors | 2023 – 2023 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Sanopharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Claes Gustav Svensson Andersch | Chief Executive Officer | 0 companies |
| Ernst Sven Oskar Andersch | Deputy Board Member | 0 companies |
| Carl Fredrik Oskar S Andersch | Board of Directors | 0 companies |
| Saeko Kato | Chairman | 0 companies |